PhaseRx, a preclinical biotech developing treatments for inherited enzyme deficiencies in the liver, raised $19 million by offering 3.7 million shares at $5, the low end of the range of $5 to $7.
PhaseRx plans to list on the Nasdaq under the symbol PZRX. Laidlaw & Company (UK) and Roth Capital acted as lead managers on the deal.
